Morphic Holding Ticks Higher After HSR Waiting Period for Eli Lilly Deal Expires
Morphic Fund Continues Share Buy-Back Effort
Morphic Fund's Latest Stock Buy-Back Figures
Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
RBC Capital Maintains Morphic(MORF.US) With Hold Rating, Maintains Target Price $57
Analysts Have Conflicting Sentiments on These Healthcare Companies: Morphic Holding (MORF), Pyxis Oncology (PYXS) and Zynex (ZYXI)
Morphic Holding (MORF) Receives a Hold From RBC Capital
Morphic | 10-Q: Quarterly report
Morphic Holding Is Maintained at Hold by Stifel
Morphic Holding Analyst Ratings
Stifel Maintains Morphic(MORF.US) With Hold Rating, Raises Target Price to $57
Stifel Nicolaus Keeps Their Hold Rating on Morphic Holding (MORF)
Express News | Morphic Holding Inc : Stifel Raises Target Price to $57 From $30
Morphic Fund Continues Share Buy-Back
Morphic Ethical Fund Continues Share Buy-Back
Morphic Ethical Equities Continues Share Buy-Back
Morphic Ethical Equities Fund Underperforms Against MSCI ACWI Index in June
Morphic Ethical Fund Reports Latest Share Buy-Back
Jefferies Downgrades Morphic Holding to Hold From Buy, Price Target Is $57
Express News | Morphic Holding Inc : Jefferies Cuts Target Price to $57 From $60